Description
Disinfection and cleaning of intact or non-seriously damaged skin (small superficial wounds).
ACTIVE INGREDIENTS:
Benalcon 0.175 cutaneous solution Active ingredient in 100 ml: Benzalkonium chloride 0.175 g.
Excipients with known effect: bergamot-based essence.
For the full list of excipients, see section 6.1.
EXCIPIENTS:
Essence based on bergamot (contains geraniol, citral, limonene, linalool), deionized water.
DOSAGE:
Benalcon 0.175 cutaneous solution.
Use pure, without diluting: apply using cotton wool, gauze or compresses.
Benalcon can be used 2 times a day.
Do not exceed the recommended dose.
WARNINGS:
The product is for external use only.
The use, especially if prolonged, of topical products can give rise to sensitization phenomena, in which case
stop treatment and undergo a medical evaluation.
Avoid contact with eyes, brain, meninges and middle ear.
Do not use for disinfection of mucous membranes.
Avoid exposure to ultraviolet rays (sun and artificial sources) after applying the product.
Do not use for prolonged treatments.
After a short period of treatment without appreciable results, a medical evaluation is necessary.
Accidental ingestion or inhalation of some disinfectants can have serious, sometimes fatal, consequences.
In case of accidental ingestion of the product, the doctor must be consulted immediately for the evaluation of the
case (see paragraph 4.9).
Important information about some of the excipients Benalcon contains essence based on bergamot which in turn contains
geraniol, citral, limonene, linalool.
Geraniol, citral, limonene and linalool may cause allergic reactions.
CONSERVATION:
Keep the container tightly closed, away from light and heat.
CONTRAINDICATIONS/SIDE EFFECTS:
Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.
INTERACTIONS:
Avoid the simultaneous use of other antiseptics and detergents.
SIDE EFFECTS:
Intolerance (burning or irritation) may occur.
Reporting of suspected adverse reactions.
Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important.
as it allows for continuous monitoring of the relationship
benefit/risk of the medicine.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazionireazioniavverse.
PREGNANCY AND BREASTFEEDING:
There are no limitations on use.
